Business
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in June 2025Generated more than $30 million of positive cash flow during the fourth quarter 2025 MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respi
About this update from Liquidia Corporation
[{"type":"image","alt":"Liquidia Technologies, Inc.","displaySize":"","headline":null,"caption":"Liquidia Technologies, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/27692c5b070211d5324fd115a83fc89f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DVUkf7FjeVJYzKXYtdS8kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/27692c5b070211d5324fd115a83fc89f","width":300,"height":96}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Received more than 2,800 unique patient prescriptions since launch in June 2025","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Generated more than $30 million of positive cash flow during the fourth quarter 2025","length":84,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":291,"olType":false},{"type":"text","content":"MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, as well as updates on the commercial launch and the clinical pipeline. These updates will be discussed during Liquidia’s participation in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–14, 2026, in San Francisco. The Company plans to report fully audited financial results for the year ended December 31, 2025, in February 2026.","length":718,"tagName":"p"},{"type":"text","content":"Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “2025 marked a transformational year for Liquidia, with the successful commercial launch of YUTREPIA across both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) patient populations. We are encouraged by the continued momentum in adoption, which reflects strong execution by our team and growing physician confidence in YUTREPIA as a differentiated a...